<DOC>
	<DOCNO>NCT00203203</DOCNO>
	<brief_summary>This phase 1 , single-blind trial evaluate use autologous bone marrow mononuclear stem cell ischemic cardiomyopathy patient . The patient must Left Ventricular Ejection Fraction ( LVEF ) less equal 45 % . Once patient meet inclusion criterion , exclusion criterion find , subject consent study , extensive baseline test perform St Luke 's Hospital Houston . Once baseline test criterion meet , patient bone marrow harvest later day subject take cardiac catheterization lab leave ventricular electromechanical mapping use NOGA software ( NOGA mapping ) perform processed stem cell injected electromechanical guidance affect area leave ventricle . The patient usually discharge home next day return follow visit week 1 , 2 , 4 , 6 , 8 , 12 , month 6 12 phone call follow-up month 4 , 5 , 7 , 8 , 9 , 10 , 11 . Patients undergo extensive test follow-up visit , include repeat cardiac catheterization NOGA map month 6 stem cell injection .</brief_summary>
	<brief_title>Autologous Stem Cells Cardiac Angiogenesis ( FOCUS HF )</brief_title>
	<detailed_description>This phase 1 , single-blind trial evaluate use autologous bone marrow mononuclear stem cell ischemic cardiomyopathy patient . The study hypothesis transendocardial injection autologous mononuclear bone marrow cell patient end-stage ischemic heart disease safe , promote neovascularization , improve perfusion myocardial contractility . The primary object study evaluate safety autologous-bone-marrow mononuclear cell injection . The secondary endpoint study assess efficacy autologous bone marrow cell improve cardiac contractile function functional outcome . The efficacy assess basis treadmill Max VO2 ( maximum volume oxygen uptake ) . Secondarily efficacy assessed basis clinical status image rest , follow-up extend 1 year enrollment.A maximum 30 patient enrol study . At end 6-month visit . require angiogram mapping non-invasive test complete , patient tell whether control active group ( stem cell therapy ) . Those control group tell final invasive testing , consent may cross active therapy arm undergo cell injection procedure ( control , stem cell therapy . In patient , foll-up angiogram mapping procedure also serve baseline procedure require cell injection . Bone marrow mononuclear cell injected identical fashion , accord criterion describe original treatment group , patient identical follow-up visit start baseline time-point extend 1 year .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>LVEF le 45 % Functional class III IV angina At least 7 % reversibility Single Photon Emission Computed Tomography ( SPECT ) nuclear study additional inc. criterion AGe &lt; 18 &gt; 70 year age Constant atrial fibrillation Left ventricular ( LV ) thrombus History malignancy last 5 year LV wall thickness &lt; 8 mm target site additional exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Autologous</keyword>
	<keyword>Cardiac</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Transplant</keyword>
</DOC>